专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20070258949A1 Human Cdna Clones Comprising Polynucleotides Encoding Polypeptides and Methods of Their Use 审中-公开
标题翻译：包含编码多肽的多核苷酸的人Cdna克隆及其使用方法
公开(公告)号：US20070258949A1
公开(公告)日：2007-11-08
申请号：US10591451
申请日：2005-03-01
申请人： Ernestine Lee , Kevin Hestir , Keting Chu , Lewis Williams
发明人： Ernestine Lee , Kevin Hestir , Keting Chu , Lewis Williams
IPC分类号： A61K38/00 , A61K48/00 , C07H21/04 , C07K14/00 , C07K16/18 , C12N15/00 , C12N15/87 , C12N5/06 , C12P1/04 , C12Q1/68 , G01N33/53
CPC分类号： C07K14/4702 , A61K38/00
摘要： The invention provides novel polynucleotides, related polypeptides related nucleic acid and polypeptide compositions corresponding to novel human cDNA clones, and related modulators, such as antibodies and small molecule modulators. The invention also provides methods to make and use these polynucleotides, polypeptides, related compositions, and modulators. These methods include diagnostic, prophylactic and therapeutic applications. The compositions and methods of the invention are useful in treating proliferative disorders, e.g., cancers, and inflammatory, immune, bacterial, and viral disorders.
摘要翻译：本发明提供了新的多核苷酸，与新的人cDNA克隆相应的相关多肽相关的核酸和多肽组合物，以及相关的调节剂，例如抗体和小分子调节剂。本发明还提供了制备和使用这些多核苷酸，多肽，相关组合物和调节剂的方法。这些方法包括诊断，预防和治疗应用。本发明的组合物和方法可用于治疗增殖性疾病，例如癌症，炎症，免疫，细菌和病毒性疾病。

12. 发明申请

US20070248605A1 Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention 审中-公开
标题翻译：成纤维细胞生长因子受体1,2,3和4作为治疗干预的目标
公开(公告)号：US20070248605A1
公开(公告)日：2007-10-25
申请号：US10583146
申请日：2004-12-17
申请人： Kevin Hestir , Kristen Pierce , Lewis Williams , Lorianne Masuoka , Justin Wong , Keting Chu
发明人： Kevin Hestir , Kristen Pierce , Lewis Williams , Lorianne Masuoka , Justin Wong , Keting Chu
IPC分类号： A61K39/395 , C07K16/22 , G01N33/53
CPC分类号： C07K16/2863 , C07K14/71 , G01N33/574 , G01N33/74 , G01N2333/50 , G01N2800/04 , G01N2800/065 , G01N2800/085 , G01N2800/102 , G01N2800/104 , G01N2800/105 , G01N2800/324
摘要： A composition is provided that contains a polypeptide and a modulator or a cell comprising the polypeptide and a modulator, where the modulator specifically interferes with the activity of the polypeptide, and the polypeptide is either FGFR3 or FGFR4, inclusive of all polymorphic forms and variants thereof. The modulator can be an antibody or active fragments thereof, a small molecule drug, an RNAi molecule, an antisense molecule or a ribozyme. A method of treatment of tumors in a subject is also provided where an antagonist of FGFR3 or FGFR4 is administered to the subject.
摘要翻译：提供了一种组合物，其包含多肽和调节剂或包含该多肽的调节剂和调节剂，其中调节剂特异性干扰多肽的活性，并且该多肽是FGFR3或FGFR4，包括所有多晶型及其变体。调节剂可以是抗体或其活性片段，小分子药物，RNAi分子，反义分子或核酶。还提供了治疗受试者的肿瘤的方法，其中向受试者施用FGFR3或FGFR4的拮抗剂。

13. 发明授权

US5962652A Antibodies to protein, FAF1 失效
标题翻译：蛋白质抗体FAF1
公开(公告)号：US5962652A
公开(公告)日：1999-10-05
申请号：US993210
申请日：1997-12-18
申请人： Keting Chu , Lewis T. Williams
发明人： Keting Chu , Lewis T. Williams
IPC分类号： A61K38/00 , A61K48/00 , C07K14/47 , C12N5/18 , C07K16/24
CPC分类号： C07K14/4747 , A61K38/00 , A61K48/00 , C07K2319/00
摘要： The present invention identifies a novel, Fas-associated factor 1 termed FAF1 which potentiates Fas-induced cell killing. The invention provides FAF1 nucleic acid and polypeptide compositions as well as methods of using these compositions in the therapeutic treatment of diseases resulting from dysregulation in apoptosis. Also provided are cells carrying and expressing the nucleic acid compositions and methods of using these cells to screen for agonists and antagonists of Fas-mediated apoptosis. Methods of isolating FAF1-interacting proteins are disclosed. Also provided are antibodies that bind FAF1, a hybridoma and a kit comprising the antibodies.
摘要翻译：本发明鉴定了一种称为FAF1的新型Fas相关因子1，其加强Fas诱导的细胞杀伤。本发明提供FAF1核酸和多肽组合物以及使用这些组合物治疗由细胞凋亡失调引起的疾病的治疗方法。还提供携带并表达核酸组合物的细胞和使用这些细胞筛选Fas介导的凋亡的激动剂和拮抗剂的方法。公开了分离FAF1相互作用蛋白的方法。还提供了结合FAF1的抗体，杂交瘤和包含抗体的试剂盒。

14. 发明授权

US5750653A Protein, FAF1, which potentiates Fas-mediated apoptosis and uses thereof 失效
标题翻译：蛋白质，FAF1，其增强Fas介导的凋亡及其用途
公开(公告)号：US5750653A
公开(公告)日：1998-05-12
申请号：US477476
申请日：1995-06-07
申请人： Keting Chu , Lewis T. Williams
发明人： Keting Chu , Lewis T. Williams
IPC分类号： A61K38/00 , A61K48/00 , C07K14/47 , C12N5/18 , C07K14/705 , A61K38/17 , G01N33/53
CPC分类号： C07K14/4747 , A61K38/00 , A61K48/00 , C07K2319/00
摘要： The present invention identifies a novel, Fas-associated factor 1 termed FAF1 which potentiates Fas-induced cell killing. The invention provides FAF1 nucleic acid and polypeptide compositions as well as methods of using these compositions in the therapeutic treatment of diseases resulting from dysregulation in apoptosis. Also provided are cells carrying and expressing the nucleic acid compositions and methods of using these cells to screen for agonists and antagonists of Fas-mediated apoptosis. Methods of isolating FAF1-interacting proteins are disclosed.
摘要翻译：本发明鉴定了一种称为FAF1的新型Fas相关因子1，其加强Fas诱导的细胞杀伤。本发明提供FAF1核酸和多肽组合物以及使用这些组合物治疗由细胞凋亡失调引起的疾病的治疗方法。还提供携带并表达核酸组合物的细胞和使用这些细胞筛选Fas介导的凋亡的激动剂和拮抗剂的方法。公开了分离FAF1相互作用蛋白的方法。

15. 发明申请

US20080112937A1 Method of Producing Autologous Embryonic Stem Cells 审中-公开
标题翻译：生产自体胚胎干细胞的方法
公开(公告)号：US20080112937A1
公开(公告)日：2008-05-15
申请号：US11632860
申请日：2005-07-19
申请人： Lewis T Williams , Hongbing Zhang , Srinivas Kothakota , Kristen Pierce , Pierre Alvaro Beaurang , Keting Chu
发明人： Lewis T Williams , Hongbing Zhang , Srinivas Kothakota , Kristen Pierce , Pierre Alvaro Beaurang , Keting Chu
IPC分类号： A61K48/00 , C12N5/08 , C12N15/09
CPC分类号： C12N5/0606 , A01K2217/05 , C12N15/873 , C12N2506/00
摘要： Aspects of the present invention relate to compositions and methods of reprogramming a somatic cell to give rise to an autologous embryonic stem cell. These methods involve providing a somatic cell of a donor subject, introducing the somatic cell into an embryo of a recipient subject to produce a chimeric embryo, allowing the chimeric embryo to develop further wherein the somatic cell will reprogram, and then selecting an autologous embryonic stem cell that has developed from the somatic cell. The methods and composition of producing pluripotent embryonic stem cells from a donor's own somatic cells invite the possibility of a number of therapeutic applications, including organ transplant and treatment of autoimmune diseases, cancer, and degenerative disorders such as diabetes, Alzheimer's, and Parkinson's.
摘要翻译：本发明的方面涉及重编程体细胞以产生自体胚胎干细胞的组合物和方法。这些方法涉及提供供体受试者的体细胞，将体细胞引入受体的胚胎以产生嵌合胚胎，允许嵌合胚胎进一步发育，其中体细胞将重新编程，然后选择自体胚胎干从体细胞发育而来的细胞。从供体自身体细胞细胞产生多能胚胎干细胞的方法和组成可引起许多治疗应用的可能性，包括器官移植和治疗自身免疫性疾病，癌症和退行性疾病如糖尿病，阿尔茨海默病和帕金森病。

16. 发明申请

US20110033456A1 METHODS OF THERAPY FOR B-CELL MALIGNANCIES USING ANTAGONIST ANTI-CD40 ANTIBODIES 失效
标题翻译：使用拮抗剂抗CD40抗体治疗B细胞恶性肿瘤的方法
公开(公告)号：US20110033456A1
公开(公告)日：2011-02-10
申请号：US12891415
申请日：2010-09-27
申请人： Keting Chu , Lorianne K. Masuoka
发明人： Keting Chu , Lorianne K. Masuoka
IPC分类号： A61K39/395 , C07K16/28 , C12N5/09 , A61P35/00
CPC分类号： C07K16/2878 , A01K2217/05 , A61K2039/505 , C07K2317/21 , C12N2799/026
摘要： Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
摘要翻译：提供了B细胞恶性肿瘤治疗方法。所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CD40抗体或其抗原结合片段。当抗体结合正常人B细胞上的CD40抗原时，拮抗性抗-CD40抗体或其抗原结合片段没有明显的激动剂活性，当抗体结合恶性人B细胞上的CD40抗原时，拮抗剂抗CD40抗体或其抗原结合片段，当抗体结合正常人B细胞上的CD40抗原时，可以显示拮抗剂活性。抗CD40抗体或其抗原结合片段的拮抗作用有益地抑制恶性人B细胞的增殖和/或分化。

17. 发明申请

US20090176664A1 High density peptide arrays containing kinase or phosphatase substrates 审中-公开
标题翻译：含有激酶或磷酸酶底物的高密度肽阵列
公开(公告)号：US20090176664A1
公开(公告)日：2009-07-09
申请号：US12156654
申请日：2008-06-02
申请人： Keting Chu
发明人： Keting Chu
IPC分类号： C40B40/10
CPC分类号： G01N33/6845 , C07K1/047
摘要： Peptide arrays and uses thereof for diagnostics, therapeutics and research. Ultra high density peptide arrays are generated using photolithography, such as using photoresist techniques.
摘要翻译：肽阵列及其用途，用于诊断，治疗和研究。使用光刻法生产超高密度肽阵列，例如使用光致抗蚀剂技术。

18. 发明授权

US07393942B2 Nucleic acids encoding mutant forms of Fas ligand 失效
标题翻译：编码Fas配体突变形式的核酸
公开(公告)号：US07393942B2
公开(公告)日：2008-07-01
申请号：US10404466
申请日：2003-04-01
申请人： Keting Chu
发明人： Keting Chu
IPC分类号： C07H21/04 , C07K1/00 , A61K39/00 , A61K39/12 , C12P21/04
CPC分类号： C07K14/70575 , A61K38/00 , C07K2319/00 , C12N2799/021 , C12N2799/022 , C12N2799/027
摘要： The invention provides for DNA encoding Fas ligand muteins and chimeras and the proteins encoded thereby. The invention further includes the use of DNA and vectors to produce transformed cells expressing the mutant or chimeric Fas ligand. When the Fas ligand of the invention is a non cleavable form, the cells expressing the Fas ligand are useful in vitro for identifying Fas expressing cells and in vitro or in vivo for reducing populations of Fas expressing cells. Thus, in other embodiments, the present invention is also directed to a method for treating a patient, for example a mammal, for autoimmune disease or transplant rejection by administering a Fas ligand therapeutic agent. The therapeutic agent is a polypeptide, a polynucleotide encoding the polypeptide or a small molecule. The polypeptides include full-length Fas ligand polypeptide, or a biologically active variant, derivative, portion, fusion or peptide thereof.
摘要翻译：本发明提供编码Fas配体突变蛋白和嵌合体的DNA及其编码的蛋白质。本发明还包括使用DNA和载体产生表达突变体或嵌合Fas配体的转化细胞。当本发明的Fas配体是不可切割的形式时，表达Fas配体的细胞在体外可用于鉴定Fas表达细胞，并在体外或体内用于减少Fas表达细胞的群体。因此，在其它实施方案中，本发明还涉及通过施用Fas配体治疗剂来治疗患者，例如哺乳动物用于自身免疫疾病或移植排斥的方法。治疗剂是多肽，编码多肽的多核苷酸或小分子。多肽包括全长Fas配体多肽或其生物活性变体，衍生物，部分，融合物或肽。

19. 发明授权

US07820170B2 Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies 失效
标题翻译：使用拮抗性抗-CD40抗体治疗B细胞恶性肿瘤的方法
公开(公告)号：US07820170B2
公开(公告)日：2010-10-26
申请号：US12568373
申请日：2009-09-28
申请人： Keting Chu , Lorianne K. Masuoka
发明人： Keting Chu , Lorianne K. Masuoka
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2878 , A01K2217/05 , A61K2039/505 , C07K2317/21 , C12N2799/026
摘要： Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
摘要翻译：提供了B细胞恶性肿瘤治疗方法。所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CD40抗体或其抗原结合片段。当抗体结合正常人B细胞上的CD40抗原时，拮抗性抗-CD40抗体或其抗原结合片段没有明显的激动剂活性，当抗体结合恶性人B细胞上的CD40抗原时，拮抗剂抗CD40抗体或其抗原结合片段，当抗体结合正常人B细胞上的CD40抗原时，可以显示拮抗剂活性。抗CD40抗体或其抗原结合片段的拮抗作用有益地抑制恶性人B细胞的增殖和/或分化。

20. 发明授权

US07611708B2 Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies 失效
标题翻译：使用拮抗性抗-CD40抗体治疗B细胞恶性肿瘤的方法
公开(公告)号：US07611708B2
公开(公告)日：2009-11-03
申请号：US12246029
申请日：2008-10-06
申请人： Keting Chu , Lorianne K. Masuoka
发明人： Keting Chu , Lorianne K. Masuoka
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2878 , A01K2217/05 , A61K2039/505 , C07K2317/21 , C12N2799/026
摘要： Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
摘要翻译：提供了B细胞恶性肿瘤治疗方法。所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CD40抗体或其抗原结合片段。当抗体结合正常人B细胞上的CD40抗原时，拮抗性抗-CD40抗体或其抗原结合片段没有明显的激动剂活性，当抗体结合恶性人B细胞上的CD40抗原时，拮抗剂抗CD40抗体或其抗原结合片段，当抗体结合正常人B细胞上的CD40抗原时，可以显示拮抗剂活性。抗CD40抗体或其抗原结合片段的拮抗作用有益地抑制恶性人B细胞的增殖和/或分化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式